1. 1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. The Lancet. 2013 Jun;381(9881):1943-55. DOI: 10.1016/S0140-6736(12)62187-410.1016/S0140-6736(12)62187-4
2. 2. Bartram CR, Schrauder A, Köhler R, Schrappe M. Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. Dtsch Arzteblatt Int. 2012 Oct;109(40):652-8.
3. 3. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2009 Jan;144(2):147-56. DOI: 10.1111/j.1365-2141.2008.07417.x10.1111/j.1365-2141.2008.07417.x
4. 4. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet Lond Engl. 2008 Mar 22;371(9617):1030-43. DOI: 10.1016/S0140-6736(08)60457-210.1016/S0140-6736(08)60457-2
5. 5. Mullighan CG, Collins-Underwood JR, Phillips LAA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor and Down syndrome associated acute lymphoblastic leukemia. Nat Genet. 2009 Nov;41(11):1243-6. DOI: 10.1038/ng.46910.1038/ng.469